Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GABA Physiology in Fragile X Syndrome
NCT04308954Phase 1Terminated
- Sponsor
- Stanford University
- Start
- Nov 2016
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 1, open-label trial (2 arms), sponsored by Stanford University. Primary endpoints: Non-displaceable binding potential of [18F]flumazenil at 2 hours and GABA (A) receptor density at 2 hours. Started Nov 2016; status: terminated.
Beyond the preview
Go deeper on NCT04308954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04308954.